1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,040 | 9,300 | 06.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.11. | enVVeno Medical Corporation: enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics Scientific Symposium | 292 | ACCESS Newswire | Featured as an emerging technology and innovation in endovascular medicine, the presentation will highlight the potential of enVVe to address the significant unmet need in deep venous diseaseThe premier... ► Artikel lesen | |
| 30.10. | enVVeno Medical GAAP EPS of -$6.29 misses by $3.94 | 1 | Seeking Alpha | ||
| 30.10. | enVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study | 478 | ACCESS Newswire | Initial 10-patient stage of U.S. pivotal study of the first-in-class enVVe non-surgical replacement venous valve on track to begin before year endCash and investments of $18.5 million expected to fund... ► Artikel lesen | |
| 29.10. | enVVeno Medical Corp - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 21.10. | enVVeno Medical Corporation: enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman | 251 | ACCESS Newswire | CEO-led series gives investors the story - straight talk, no B.S., no corporate spinReal answers to what investors need to know about enVVeno and why they need to know itWatch the next episode here... ► Artikel lesen | |
| 02.10. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | 2.783 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| ENVVENO MEDICAL Aktie jetzt für 0€ handeln | |||||
| 02.10. | enVVeno Medical Corporation: enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial | 783 | ACCESS Newswire | Leading venous interventionalist Karen B. Garby, MD, DABVLM, RPhS, to present the enVVe System, a minimally invasive replacement venous valve currently being evaluated in a U.S. pivotal studyAn estimated... ► Artikel lesen | |
| 16.09. | enVVeno Medical Corporation: enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series | 452 | ACCESS Newswire | New CEO-led video series provides investors with straight talk, just the facts, with no B.S. or corporate spinReal answers to what investors need to know about enVVeno and why they need to know itWatch... ► Artikel lesen | |
| 11.09. | enVVeno Medical Corporation: enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand | 396 | ACCESS Newswire | Access the video webcast here IRVINE, CA / ACCESS Newswire / September 11, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded... ► Artikel lesen | |
| 27.08. | enVVeno Medical Corporation: enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference | 507 | ACCESS Newswire | Video Webcast Now Available Here IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman, Chief... ► Artikel lesen | |
| 04.08. | enVVeno Medical Corporation: Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments | 501 | ACCESS Newswire | Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence... ► Artikel lesen | |
| 31.07. | enVVeno Medical wins FDA IDE for non-surgical transcatheter replacement venous valve | 1 | MassDevice | ||
| 31.07. | enVVeno Medical erhält FDA-Zulassung für zulassungsrelevante Studie | 2 | Investing.com Deutsch | ||
| 31.07. | enVVeno Medical GAAP EPS of -$5.37 misses by $2.10 | 2 | Seeking Alpha | ||
| 31.07. | enVVeno Medical Corporation: enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve | 595 | ACCESS Newswire | Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway... ► Artikel lesen | |
| 30.07. | enVVeno Medical Corp - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 15.07. | enVVeno Medical Corporation: enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment | 532 | ACCESS Newswire | CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe to Own a Multi-Billion-Dollar Venous Disease MarketWatch the "What This Means" video here IRVINE... ► Artikel lesen | |
| 14.07. | enVVeno Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 07.07. | enVVeno Medical receives U.S. patent for venous valve system | 2 | Investing.com | ||
| 07.07. | enVVeno Medical Corporation: enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial | 1.085 | ACCESS Newswire | New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billion-Dollar... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 40,960 | +0,59 % | Fresenius Medical Care-Aktie: Seitwärts statt Aufbruch - lohnt sich der Einstieg?" | Die Fresenius Medical Care-Aktie befindet sich weiterhin in einem ausgeprägten Seitwärtstrend. Die Handelsspanne liegt derzeit zwischen 37 und 41 €. Am Mittwoch notiert das Papier bei 39,10 €. Der am... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 43,130 | +0,44 % | EQS-AFR: Siemens Healthineers AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Siemens Healthineers AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Siemens Healthineers AG: Vorabbekanntmachung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 33,820 | +0,24 % | EQS-AFR: Carl Zeiss Meditec AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Carl Zeiss Meditec AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Carl Zeiss Meditec AG: Vorabbekanntmachung... ► Artikel lesen | |
| ECKERT & ZIEGLER | 13,710 | -0,80 % | Eckert&Ziegler erhält GMP-Zertifizierung: Warum der nächste Schub greifbar wird | ||
| INTUITIVE SURGICAL | 399,25 | -0,99 % | ISRG Gains 7.8% in 6 Months: Will the Share Price Recovery Continue? | ||
| MEDTRONIC | 90,68 | -0,35 % | Medtronic: What Wild Hearts Reveal | Medtronic LINQ insertable cardiac monitors track animal heart activity worldwide, revealing insights into stress, survival, and what "normal" means across species. NORTHAMPTON, MA / ACCESS Newswire... ► Artikel lesen | |
| GERRESHEIMER | 31,680 | +1,47 % | EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Gerresheimer AG
Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of... ► Artikel lesen | |
| THERMO FISHER | 643,00 | -0,12 % | Thermo Fisher Scientific (TMO) Is Benefiting From More Than Healthcare Demand: Here's the Overlooked AI Connection | ||
| TELADOC HEALTH | 7,920 | -1,17 % | Teladoc Health, Inc.: Teladoc Health Announces Chief Legal Officer Transition | NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced a leadership transition in its legal function. After 11 years with... ► Artikel lesen | |
| STRATEC | 25,200 | +0,80 % | DEUTSCHE BANK RESEARCH stuft STRATEC BIOMEDICAL SYSTEMS AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Stratec nach einer Gewinnwarnung für 2026 auf "Hold" mit einem Kursziel von 21 Euro belassen. Mit einer Senkung der Jahresziele... ► Artikel lesen | |
| RHOEN-KLINIKUM | 14,500 | 0,00 % | EQS-News: RHÖN-KLINIKUM Aktiengesellschaft: RHÖN-KLINIKUM AG zieht Bilanz für drittes Quartal 2026 | EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Schlagwort(e): 9-Monatszahlen/Quartalsergebnis
RHÖN-KLINIKUM AG zieht Bilanz für drittes Quartal 2026
05.11.2026 / 09:02 CET/CEST
Für... ► Artikel lesen | |
| M1 AESTHETICS | 13,000 | 0,00 % | Dividendenbekanntmachungen (08.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2 MILK COMPANY LIMITED NZATME0002S8 0,4135 NZD 0,2059 EUR AGRANA BETEILIGUNGS-AG AT000AGRANA3 - 0,35 EUR BANK OF CHONGQING CO LTD CNE100001QN2 0... ► Artikel lesen | |
| EUROFINS SCIENTIFIC | 88,24 | +0,07 % | Eurofins Scientific SE: Eurofins Scientific: Director/PDMR Shareholding | Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 14,550 | -0,07 % | LifeStance Health Prices Secondary Public Offering Of 45 Mln Shares At $13.12/Shr | ||
| GENEDX | 54,93 | +0,18 % | Why GeneDx Holdings Stock Just Dropped 16.6% |
Das Unternehmen ENVVENO MEDICAL CORPORATION kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -100,00 % bei einem Aktienkurs von 9,170 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENVVENO MEDICAL CORPORATION finden Sie auf Wallstreet Online.